CN101732276A - 一种单硝酸异山梨酯的片剂 - Google Patents
一种单硝酸异山梨酯的片剂 Download PDFInfo
- Publication number
- CN101732276A CN101732276A CN200910215422A CN200910215422A CN101732276A CN 101732276 A CN101732276 A CN 101732276A CN 200910215422 A CN200910215422 A CN 200910215422A CN 200910215422 A CN200910215422 A CN 200910215422A CN 101732276 A CN101732276 A CN 101732276A
- Authority
- CN
- China
- Prior art keywords
- tablet
- layer
- isosorbide mononitrate
- medicine
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003827 isosorbide mononitrate Drugs 0.000 title claims abstract description 56
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 title claims abstract description 55
- 230000003204 osmotic effect Effects 0.000 claims abstract description 47
- 238000013270 controlled release Methods 0.000 claims abstract description 31
- 238000000576 coating method Methods 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 230000000149 penetrating effect Effects 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 26
- -1 polyoxyethylene Polymers 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 16
- 229920002301 cellulose acetate Polymers 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 6
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000000052 vinegar Substances 0.000 claims description 6
- 235000021419 vinegar Nutrition 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000003361 porogen Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical group CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 49
- 238000002360 preparation method Methods 0.000 abstract description 33
- 229940079593 drug Drugs 0.000 abstract description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 239000011148 porous material Substances 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000005086 pumping Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 47
- 239000003826 tablet Substances 0.000 description 39
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002356 single layer Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical class [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910215422A CN101732276B (zh) | 2009-12-26 | 2009-12-26 | 一种单硝酸异山梨酯的片剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910215422A CN101732276B (zh) | 2009-12-26 | 2009-12-26 | 一种单硝酸异山梨酯的片剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732276A true CN101732276A (zh) | 2010-06-16 |
CN101732276B CN101732276B (zh) | 2012-09-12 |
Family
ID=42456650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910215422A Active CN101732276B (zh) | 2009-12-26 | 2009-12-26 | 一种单硝酸异山梨酯的片剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732276B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293760A (zh) * | 2011-03-04 | 2011-12-28 | 上海医药集团股份有限公司 | 一种单硝酸异山梨酯择时控释制剂及其制备方法 |
CN102423305A (zh) * | 2011-12-23 | 2012-04-25 | 中国药科大学 | 单硝酸异山梨酯微孔渗透泵片及其制备方法 |
CN102670542A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 盐酸曲马多渗透泵控释片 |
CN102670560A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 氯沙坦钾渗透泵控释片 |
CN102670538A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 单硝酸异山梨酯渗透泵控释片 |
CN102670543A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 渗透泵型单硝酸异山梨酯速-控释片 |
CN102688212A (zh) * | 2012-05-29 | 2012-09-26 | 北京均大高科科技孵化器有限公司 | 一种单硝酸异山梨酯缓释片及其制备方法 |
CN103655508A (zh) * | 2013-12-24 | 2014-03-26 | 合肥立方制药股份有限公司 | 一种双药物层单硝酸异山梨酯渗透泵控释片及制备方法 |
CN114831952A (zh) * | 2017-12-26 | 2022-08-02 | 合肥立方制药股份有限公司 | 一种单硝酸异山梨酯渗透泵控释片及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100574748C (zh) * | 2003-12-15 | 2009-12-30 | 北京科信必成医药科技发展有限公司 | 择时释放渗透泵控释片 |
CN1692906B (zh) * | 2005-03-01 | 2010-11-10 | 沈阳药科大学 | 双面打孔的单室双层渗透泵控释系统 |
CN101342151A (zh) * | 2007-07-11 | 2009-01-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 |
CN101455666A (zh) * | 2007-12-14 | 2009-06-17 | 北京中惠药业有限公司 | 尼莫地平双层渗透泵控释片及其制备工艺 |
CN101485639B (zh) * | 2008-01-18 | 2011-04-20 | 普尔药物科技开发(深圳)有限公司 | 石杉碱甲双层渗透泵控释片 |
-
2009
- 2009-12-26 CN CN200910215422A patent/CN101732276B/zh active Active
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293760A (zh) * | 2011-03-04 | 2011-12-28 | 上海医药集团股份有限公司 | 一种单硝酸异山梨酯择时控释制剂及其制备方法 |
CN102293760B (zh) * | 2011-03-04 | 2015-03-18 | 上海医药集团股份有限公司 | 一种单硝酸异山梨酯择时控释制剂及其制备方法 |
CN102670538A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 单硝酸异山梨酯渗透泵控释片 |
CN102670542A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 盐酸曲马多渗透泵控释片 |
CN102670560A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 氯沙坦钾渗透泵控释片 |
CN102670543A (zh) * | 2011-03-17 | 2012-09-19 | 北京天衡药物研究院 | 渗透泵型单硝酸异山梨酯速-控释片 |
CN102423305A (zh) * | 2011-12-23 | 2012-04-25 | 中国药科大学 | 单硝酸异山梨酯微孔渗透泵片及其制备方法 |
CN102688212A (zh) * | 2012-05-29 | 2012-09-26 | 北京均大高科科技孵化器有限公司 | 一种单硝酸异山梨酯缓释片及其制备方法 |
CN102688212B (zh) * | 2012-05-29 | 2013-08-07 | 北京均大高科科技孵化器有限公司 | 一种单硝酸异山梨酯缓释片及其制备方法 |
CN103655508A (zh) * | 2013-12-24 | 2014-03-26 | 合肥立方制药股份有限公司 | 一种双药物层单硝酸异山梨酯渗透泵控释片及制备方法 |
CN114831952A (zh) * | 2017-12-26 | 2022-08-02 | 合肥立方制药股份有限公司 | 一种单硝酸异山梨酯渗透泵控释片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101732276B (zh) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101732276B (zh) | 一种单硝酸异山梨酯的片剂 | |
KR101365031B1 (ko) | 오피오이드 서방성 경구 제형을 위한 알코올유도 용량덤핑의 감소 방법 | |
CN100563638C (zh) | 硝苯地平控释片及其制备方法 | |
CN101732275B (zh) | 一种单硝酸异山梨酯双层渗透泵控释片及其制备方法 | |
KR20090038392A (ko) | 방출 증진제를 포함하는 삼투 약물 전달 시스템 | |
CN102138912A (zh) | 硝苯地平渗透泵控释片及其制备工艺 | |
CN102626428B (zh) | 一种银杏叶提取物渗透泵控释制剂及其制备方法 | |
CN102349880B (zh) | 伊拉地平控释片及其制备方法 | |
CN101342151A (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
CN103271889B (zh) | 帕利哌酮新型递增释放渗透泵制剂及其制备方法 | |
CN100571783C (zh) | 格列吡嗪控释片及其制备方法 | |
CN103655508B (zh) | 一种双药物层单硝酸异山梨酯渗透泵控释片及制备方法 | |
CN104644599B (zh) | 单硝酸异山梨酯微孔渗透泵控释制剂及其制备方法 | |
CN101829069A (zh) | 匹伐他汀钙双层渗透泵控释片及其制备方法 | |
CN101642443B (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
CN102293760B (zh) | 一种单硝酸异山梨酯择时控释制剂及其制备方法 | |
CN102525991A (zh) | 一种含有盐酸吡格列酮和盐酸二甲双胍的复方制剂及其制备方法 | |
CN103006566B (zh) | 氯沙坦钾与氢氯噻嗪固体分散体或包合物的渗透泵控释片 | |
CN100463676C (zh) | 一种盐酸文拉法辛控释片制剂及其制备方法 | |
CN104887639B (zh) | 盐酸曲美他嗪单层渗透泵控释片及制备方法 | |
CN109394732A (zh) | 盐酸青藤碱肠溶定位渗透泵控释胶囊及其制备方法 | |
CN103027898B (zh) | 一种西他列汀缓释微丸及其制备方法 | |
CN103599099A (zh) | 银杏内酯双层渗透泵控释片及制备方法 | |
CN110711183A (zh) | 复方盐酸二甲双胍渗透泵控释胶囊及其制备方法 | |
CN105663069A (zh) | 一种释药完全的单硝酸异山梨酯渗透泵片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000513 Denomination of invention: Tablet of isosorbide mononitrate License type: Exclusive License Open date: 20100616 Record date: 20100909 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000513 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100616 Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2013370000261 Denomination of invention: Tablet of isosorbide mononitrate Granted publication date: 20120912 License type: Exclusive License Record date: 20131210 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161229 Address after: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee after: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Address before: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190327 Address after: 276005 Law and Patent Affairs Department, No. 209 Hongqi Road, Linyi City, Shandong Province Patentee after: LUNAN PHARMACEUTICAL Group Corp. Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee before: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230625 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Address before: 276005 Law and Patent Affairs Department, No. 209 Hongqi Road, Linyi City, Shandong Province Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
TR01 | Transfer of patent right |